This year, we got exciting new data about an HIV drug in development that may become an every-six-month, self-administered antiretroviral injection. But we learned about it via press release, rather than carefully presented research.
Because the public is getting so many mixed messages, it’s our responsibility to provide clarity and moderate optimism.
HVTN 702 is but one of many vaccine trials underway, researchers note.
This may be a temporary setback, but long-acting antiretroviral therapy is still on the way, experts say.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Providers, payers, and health systems need to catch up, said Melanie Thompson, M.D., at the ACTHIV conference.
Richard Jefferys, an expert in HIV cure research, spoke to TheBodyPro about this new case of HIV remission -- and the danger in rushing to publish these stories, especially for people who live with stigma.
A new class of cancer drugs -- topoisomerase inhibitors -- is now in use in the United States for treating certain cancers. But despite laboratory studies and other reason to believe that these drugs might also work as antiretrovirals, they have neve...